Synopsis:
Thyrocare Technologies Limited reported an 80.86 percent increase in Net profit YoY in Q2FY26 indicating the company is improving operational efficiency. Followed by Bonus and Dividend announcements.
The shares of a small-cap firm providing affordable, high-quality diagnostic testing services to patients, hospitals, and laboratories across India gained investor attention after announcing its Q2FY26 results and business updates.
With a market capitalization of Rs.6,784.88 crores, the shares of Thyrocare Technologies Limited were trading at Rs.1,280.30, up by 1.24 percent from its previous day closing price of Rs.1,264.60. It made a high of Rs. 1,470.
Q2FY26 Results, Bonus and Dividend
Thyrocare Technologies Limited reported revenue of Rs.216.53 crore in Q2FY26, up by 22.08 percent from Rs.177.36 crore in Q2FY25, and up by 12.17 percent compared to Rs.193.03 crore in the previous quarter.
The company’s net profit stood at Rs.47.81 crore in Q2FY26, rising to 80.96 percent from Rs.26.42 crore a year ago and up by 24.86 percent from Rs.38.29 crore in the previous quarter.
The Board has approved a 2:1 bonus share issue, where shareholders will receive two shares for every one held, using up to Rs.106.11 crore from the company’s reserves, subject to necessary shareholder and regulatory approvals. Additionally, an interim dividend of Rs.7 per equity share of Rs.10 face value, representing 70 percent, was declared.
The company showed strong growth, with the number of tests rising 21 percent from 44 million in Q2FY25 to 53.3 million in Q2FY26, supported by a 13 percent increase in patients, from 4,4 millions to 5 millions for the same period. Active franchises grew 20 percent, from 8,446 to 10,159 for the same period.
Also read: ₹2,500 Cr Order: Power stock in focus after receiving Thermal Power project from BHEL
Revenue per patient increased 10 percent from Rs.368 in Q2FY25 to Rs.406 in Q2FY26. Revenue per test increased 2 percent, from Rs.37.1 to Rs.38 for the same period .The tests per patient also increased by 8 percent from 9.9 to 10.7 for the same period.
The company’s consolidated revenue grew 22 percent year-on-year, driven by a 24 percent rise in the Pathology segment. Franchise revenue increased 20 percent year on year , and partnership revenue rose 35 percent. Profitability was strong, with a 72% gross margin.The consolidated EBITDA has 48 percent year on year growth, and 82 percent PAT growth. The company is debt-free with over INR 190 Crores in cash and investments. To support expansion, four new labs opened in Vijayawada, Bhagalpur, Roorkee, and Kashmir.
Thyrocare Technologies Limited operates in the healthcare sector, offering reliable and affordable diagnostic services to patients, hospitals, and laboratories across India. The company focuses on expanding its reach through a network of franchises and collection centers, ensuring convenient access to testing services.It is known for its emphasis on advanced technology, reliable results, and efficient operations, making it a trusted name in the diagnostic industry.
Written By Jhanavi Sivakumar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Stock skyrockets 16% after company’s net profit increases 81% YoY appeared first on Trade Brains.